



Pharmaceutical **DIGITAL HEALTH INNOVATION INDEX**

GLOBAL DIGITAL HEALTH 2021 • THEMATIC REPORT

**TOP 25 PHARMACEUTICALS • PARTNERSHIPS
VENTURE SPOTLIGHT • GLOBAL TRENDS**



Galen Growth is pleased to share with you this inaugural report indexing the most active pharmaceutical and biopharmaceutical companies in the Digital Health innovation ecosystem around the globe.

In this first-of-its-kind annual analysis, we have assessed each Digital Health venture portfolio with a focus on the strategic fit of the portfolio to the corporation and the potential success of the ventures contained within.

With unmatched, unparalleled and indispensable coverage of the global Digital Health ecosystems, this report is powered by HealthTech Alpha, a Galen Growth proprietary solution, and the world's leading on-demand Digital Health private market data, analytics and intelligence platform.



FOREWORD

Digital Health is now ten years old and in great health! With a 5-year CAGR of 13% (2015 – 2020), the number of new ventures reaching the market is naturally slowing, and **ventures are maturing in capability**. Meanwhile, exits reached a global total of 162 so far in 2021, already exceeding the exits in 2020 by 35% with still a month left in the year.

With ventures building momentum and proof points, the **ecosystem must also mature**, including pharmaceutical and biopharmaceutical companies (pharmaceuticals) that are busily integrating Digital Health within their business.

Pharmaceuticals have indeed been active in Digital Health ecosystems during the past decade. Recent Galen Growth analysis, however, concluded that only **30 pharmaceuticals are accountable for approx. 80% of partnerships with Digital Health ventures globally**. Many of these companies have built up sizeable portfolios of partnerships with Digital Health ventures despite their continuous restructures, governance model and priority changes!

Until now, **integration of Digital Health by pharmaceuticals has lacked focus** and has primarily been based on testing new ideas and gaining experience. It was not possible to develop a global, cohesive digital strategy because the endpoint of Digital Health were still too uncertain.

Now, as we near the end of 2021, Digital Health is not only penetrating deep into the hearts of pharmaceuticals by changing not only the way drugs are discovered and clinical trials are run, but it is also **changing the relationship between the pharmaceuticals and the patient**. Regulators and health systems are also stepping up and introducing the much-needed frameworks to speed up adoption.

Market expectations are therefore changing fast, accelerated by the now two-year-old pandemic. So much so, we believe that the époque of ad-hoc bilateral and experimental partnerships which both parties attempt to scale are now being superseded by the **era of Digital Health integrated solutions**.

Therefore, Galen Growth sees an **imminent need for pharmaceuticals to conduct a detailed portfolio analysis** to ensure alignment and confirm that they are optimally suited to meet the fast-changing needs of the market.



CONTENTS

INTRODUCTION	5
GALEN GROWTH DIGITAL HEALTH INNOVATION INDEX	5
TOP 10 STRATEGIC FIT	6
TOP 10 VENTURE PORTFOLIO SCORE	7
PHARMA PROFILES	9
METHODOLOGY	14
CRITICAL SUCCESS FACTORS	16
DEEP DIVE PHARMACEUTICAL PARTNERSHIPS	17
KEY INFORMATION	22
ABOUT GALEN GROWTH	26




INTRODUCTION

In order to move quickly and incorporate the unique value of Digital Health, pharmaceutical companies must partner with ventures that have Digital Health products and the skills needed to successfully develop Digital Health solutions. Galen Growth has developed the **Pharmaceutical Digital Health Innovation Index** in order to evaluate the portfolios of Digital Health venture partners for the pharmaceuticals with portfolios.

This portfolio analysis focuses on two critical aspects: first, the strategic fit of the portfolio to the pharmaceutical; second, the strength of the venture portfolio. Each company has their unique interests in Digital Health, so this portfolio analysis is not intended to replace a unique strategy. It is however intended to indicate the strengths and weaknesses in order to inform the next generation of focused Digital Health portfolios.

GALEN GROWTH DIGITAL HEALTH INNOVATION INDEX 2021





Pharmaceutical - Digital Health Innovation Index 2021

Top Strategic Fit

The top performers in the Strategic Fit analysis have been quick to focus their portfolios to make an impact across their entire value chain – from Research to Patient Support Programs. In addition, they understand the need to partner with ventures that have a local focus and therefore have a global portfolio of ventures. Finally, there is strong alignment between the target therapeutic areas of the pharmaceutical and the focus areas of the ventures, which is critical when focusing on the patients' needs.

Strategic Fit Ranking	Company Name	Portfolio Score Ranking
1	Roche	17
2	AstraZeneca	13
3	Novartis	12
4	Lilly	7
5	Lundbeck	8
6	Sanofi	20
7	Pfizer	14
8	Takeda	19
9	Merck & Co.	5
10	Amgen	15

Pharmaceutical - Digital Health Innovation Index 2021

Top Venture Portfolio Score

The choice of ventures for partnering will determine the success of the partnerships and the speed to market of the solution to solve a pain point. Partnering with mature ventures that have a proven leadership team will improve chances of success, whilst partnering with less mature ventures, although potentially under-the-radar, carries a higher risk and often requires more effort from the pharmaceutical partner and a longer pathway to ROI. It should be clarified, however, that partnerships with highly mature ventures that are not aligned with the strategic priorities of the pharmaceutical results in Digital Health theatrics with little added value to the patient or business, beyond PR.

Portfolio Score Ranking	Companies	Strategic Fit Ranking
1	Novo Nordisk	23
2	Daiichi Sankyo	21
3	Bristol-Myers Squibb	18
4	Abbott	24
5	Merck & Co.	9
6	Janssen	16
7	Lilly	4
8	Lundbeck	5
9	Gilead Sciences	22
10	Astellas	25

DIGITAL HEALTH INNOVATION INDEX - Pharmaceutical

Developing an Innovation Index looks not only at the efforts of the pharmaceutical to integrate Digital Health into its business model, but also the degree to which the pharmaceutical has selected successful Digital Health ventures to develop partnerships.

Has the company made Digital Health a strategic priority across the global organization? Has the pharmaceutical ... ?:

- distributed partnerships globally
- integrated Digital Health into the strategic therapeutic areas
- broadly integrated Digital Health across the research organization as well as the Patient / HCP Journey
- developed a large enough portfolio to have gained practical knowledge from experience



Strategic Fit

Portfolio Strength



Does the portfolio include Digital Health ventures that will contribute to the success of the partnerships and the speed to market of the solution? Do they have ... ?:

- strong management team
- innovative product
- financial strength
- proven digital health maturity

SCOPE : The analysis considers ventures in the four major global regions for Digital Health: Asia Pacific, the Middle East, Western Europe (key ecosystems), and North America.



Galen Growth Digital Health Innovation Index 2021

OPTIMAL PERFORMERS

Lilly **ELI LILLY**

#1




Strategic Fit



Venture Score

Portfolio Distribution in Core Therapeutic Areas *(selected ventures, not a complete list)*



PARTNERSHIPS	39
NORTH AMERICA	51%
ASIA PACIFIC	36%
EUROPE	13%
VALUE CHAIN LINKS	11 out of 12
KEY THERAPEUTIC AREAS	4 out of 5

Lundbeck **LUNDBECK**

#2





Strategic Fit



Venture Score

Portfolio Distribution in Core Therapeutic Areas *(selected ventures, not a complete list)*



PARTNERSHIPS	7
NORTH AMERICA	17%
ASIA PACIFIC	33%
EUROPE	50%
VALUE CHAIN LINKS	11 out of 12
KEY THERAPEUTIC AREAS	1 out of 1



Galen Growth Digital Health Innovation Index 2021

OPTIMAL PERFORMERS

AstraZeneca  **ASTRAZENECA**

#3




Strategic Fit



Venture Score

PARTNERSHIPS	68
NORTH AMERICA	25%
ASIA PACIFIC	56%
EUROPE	18%
VALUE CHAIN LINKS	11 out of 12
KEY THERAPEUTIC AREAS	5 out of 5

Portfolio Distribution in Core Therapeutic Areas (selected ventures, not a complete list)



NOVARTIS  **NOVARTIS**

#4




Strategic Fit



Venture Score

PARTNERSHIPS	81
NORTH AMERICA	37%
ASIA PACIFIC	36%
EUROPE	26%
MIDDLE EAST	1%
VALUE CHAIN LINKS	11 out of 12
KEY THERAPEUTIC AREAS	7 out of 7

Portfolio Distribution in Core Therapeutic Areas (selected ventures, not a complete list)



Galen Growth Digital Health Innovation Index 2021

OPTIMAL PERFORMERS



#5




Strategic Fit



Venture Score

Portfolio Distribution in Core Therapeutic Areas *(selected ventures, not a complete list)*



PARTNERSHIPS	44
NORTH AMERICA	55%
ASIA PACIFIC	32%
EUROPE	11%
VALUE CHAIN LINKS	10 out of 12
KEY THERAPEUTIC AREAS	4 out of 4



#6




Strategic Fit



Venture Score

Portfolio Distribution in Core Therapeutic Areas *(selected ventures, not a complete list)*



PARTNERSHIPS	66
NORTH AMERICA	29%
ASIA PACIFIC	42%
EUROPE	27%
MIDDLE EAST	2%
VALUE CHAIN LINKS	11 out of 12
KEY THERAPEUTIC AREAS	3 out of 5

Galen Growth Digital Health Innovation Index 2021

TOP PERFORMERS* | STRATEGIC FIT



ROCHE

#1




Strategic Fit



Venture Score

Portfolio Distribution in Core Therapeutic Areas *(selected ventures, not a complete list)*



PARTNERSHIPS	88
NORTH AMERICA	39%
ASIA PACIFIC	33%
EUROPE	23%
MIDDLE EAST	5%
VALUE CHAIN LINKS	11 out of 12
KEY THERAPEUTIC AREAS	7 out of 7



SANOFI

#6

* NOTE: Rankings #2 - #5: AstraZeneca, Novartis, Lilly, and Lundbeck were analysed in the Optimal Performance section.




Strategic Fit



Venture Score

Portfolio Distribution in Core Therapeutic Areas *(selected ventures, not a complete list)*



PARTNERSHIPS	52
NORTH AMERICA	40%
ASIA PACIFIC	44%
EUROPE	8%
MIDDLE EAST	8%
VALUE CHAIN LINKS	11 out of 12
KEY THERAPEUTIC AREAS	7 out of 7



Galen Growth Digital Health Innovation Index 2021

TOP PERFORMERS | PORTFOLIO SCORE



NOVO NORDISK

#1




Strategic Fit



Venture Score

Portfolio Distribution in Core Therapeutic Areas

(selected ventures, not a complete list)



PARTNERSHIPS	22
NORTH AMERICA	55%
ASIA PACIFIC	36%
EUROPE	5%
MIDDLE EAST	5%
VALUE CHAIN LINKS	11 out of 12
KEY THERAPEUTIC AREAS	2 out of 4



DAIICHI SANKYO

#2




Strategic Fit



Venture Score

Portfolio Distribution in Core Therapeutic Areas

(selected ventures, not a complete list)



PARTNERSHIPS	6
NORTH AMERICA	33%
ASIA PACIFIC	50%
EUROPE	17%
VALUE CHAIN LINKS	9 out of 12
KEY THERAPEUTIC AREAS	2 out of 3



Pharmaceutical - Digital Health Innovation Index

Methodology

STRATEGIC FIT METHODOLOGY

A Digital Health portfolio of a pharmaceutical should reflect the commitment of the global corporation to adopt Digital Health into the fabric of the company and to push it into the therapeutic focus areas with the highest strategic priority. Strategic Fit considers:

Global Venture Distribution. The portfolio analyses only multi-national pharmaceutical companies, and therefore it is expected that the Digital Health ventures are also distributed globally to focus on solutions for the entire patient population.

Alignment with the Core Strategic Therapeutic Areas. The venture portfolio has been compared to the publicly stated core therapeutic areas for each pharmaceutical to assess the alignment and the commitment from the pharmaceutical to integrate Digital Health into the highest priority areas of its business.

Broadly Integrated across the Pharmaceutical and Healthcare Value Chains. Digital Health solutions are available to improve results across the entire pharmaceutical and healthcare value chains, from Research to Patient Support Programs. Therefore, the analysis assesses the number of links in the value chain that are addressed by the ventures in the pharmaceutical Digital Health portfolio.

Number of Digital Health Venture Partnerships. With a stronger commitment to Digital Health, the number of Digital Health venture partnerships will increase. For this analysis, the number of partnerships has been evaluated in proportion to the size of the pharmaceutical.



Pharmaceutical - Digital Health Innovation Index

Methodology

PORTFOLIO STRENGTH METHODOLOGY

A strong Digital Health partnership portfolio reduces the risk of partnership failure (although this can never be eliminated), and it ensures a minimum time-to-market for the product. Portfolio strength considers:

Venture management team. The optimal management team for a Digital Health ventures includes members with experience from previous successful startups. In addition, it should include members with a strong educational background in relevant fields.

Venture maturity. Galen Growth's proprietary venture maturity score includes the following indices:

- **Momentum index:** Evaluates the maturity and performance of the Digital Health venture relative to itself and ecosystem peers
 - **Market index:** Measures the health of the sector category and sub-category in which a venture competes
 - **Money index:** Quantifies the financial strength and wellbeing of a Digital Health venture based on its financial history, and investor quality
 - **Innovation index:** Assesses the relevance of a Digital Health venture to the ecosystem
-

GENERAL CONSTRAINTS

This analysis take a snapshot of Digital Health portfolios of the most active, multi-national pharmaceutical and biopharmaceutical companies. Therefore, pharmaceuticals that are locally or regionally focused are not included in the analysis. pharmaceuticals that have less than five partnerships with private ventures in Galen Growth's focus geographic regions are not considered and partnering relationships that are limited to accelerator programs are not considered. Finally, only partnerships with private ventures are included in the analysis.



Pharmaceutical - Digital Health Innovation Index Becoming or Remaining Optimal

To succeed, which they must, pharmaceuticals will need to take full advantage of the maturing Digital Health ecosystem and either evaluate their existing Digital Health portfolios or build a new Digital Health portfolio.

To be Optimal, their portfolio will need to address the following Critical Success Factors (CSFs):

- Be aligned to key Therapeutic Areas
- Have a broad distribution of solutions across the value chain
- Pinpoint high-potential ventures
- Be relevant to impacted touchpoints at a local, regional and global level
- Address fast evolving market expectations

Galen Growth is uniquely positioned to assist portfolio evaluations and new partner searches with HealthTech Alpha, the world's leading Digital Health private market data, analytics and intelligence. Evaluations are based on data and no hype nor bias, leading to better informed decisions and clear understanding of the global Digital Health ecosystems.

DEEP DIVE: DIGITAL HEALTH PARTNERSHIPS WITH PHARMACEUTICALS






Global Partnership Distribution in Digital Health


Galen Growth has recorded more than 22,000 partnerships globally with Digital Health ventures since 2012, and 6% of those partnerships are with pharmaceutical companies. Other partnerships are recorded with insurance companies, hospitals, academia, institutions, tech companies, other Digital Health ventures, government, and other organizations.

Share of Pharma Partnerships vs all Partnerships



Focusing solely on the partnerships between Digital Health ventures and pharmaceuticals, only a fraction of the total global pharmaceuticals have developed multiple partnerships. The Pareto diagram below shows that the top 10 pharmaceuticals (ranked by number of partnerships with Digital Health ventures) capture 50% of the partnerships with Digital Health ventures globally. The top 20 pharmaceuticals capture a total of 70% of partnerships, leaving the remaining 250+ pharmaceuticals with only 30% of the total partnerships.

Pareto Chart of Partnerships by Most Active Pharmaceuticals






Global Partnership Distribution by Geography

Analysis of the partnerships reveals that the most partnerships (64%) have been developed between pharmaceuticals and ventures in China and the United States. For comparison, 37% of all ventures globally are headquartered in these two countries.


Normalizing by the total number of ventures with pharmaceutical partners in each country, we can look at the data through the lens of the venture. With this approach of the average number of pharmaceutical partners per venture, Digital Health ventures in Germany take the top spot with an average of three pharmaceutical partners per venture. China captures the number 2 spot, while the United States places 7th. It is notable that Asian countries with very few Digital Health ventures, such as Vietnam and the Philippines, rank in the top 10 because pharmaceuticals are eager to reach patients through Digital Health solutions and have a smaller selection of ventures available.

Looking at the share of ventures within a country that are actively engaged in partnering with pharmaceuticals provides insights into the penetration of pharmaceuticals into the Digital Health venture market of that country. 6 countries in APAC are at the top of the list. The placement of Germany at #17 indicates that there are only a few ventures with a significant number of partnerships, therefore giving a high number of pharmaceutical partners per venture while leaving the share of ventures with pharmaceutical partners low.


Total Number of Partnerships with Pharma
(countries with more than 10 partnerships)



Average Number of Pharma Partners per Venture
(countries with more than 1 partner per venture)




Share of Ventures with Pharma Partners
(countries with more than 5% share)



Global Partnership Distribution by Cluster

Among the top 25 pharmaceuticals most active in partnering, 22% of the Digital Health partnerships have focused on solutions in the Patient Solutions cluster, which includes digital therapeutics (DTx), disease management, and self-diagnosis tools, while 21% of the partnerships have focused on solutions in the Research cluster.

Galen Growth's Digital Health Taxonomy can be found on page 24 of the report.



- Patient Solutions
- Research
- Health Management Solutions
- Medical Diagnostics
- Telemedicine
- Remote Monitoring
- Online Health Communities
- Other Clusters

Spotlight:

Ventures with 10 or More Pharmaceutical Partnerships



Apricot Forest (杏树林)

COUNTRY	PRIMARY CATEGORY	DESCRIPTION
China	EHR / EMR	Apricot Forest (杏树林) addresses the HCP shortage issue in China by facilitating the professional growth of doctors and improving the efficiency of the medical system. Solutions include professional medical records and patient management tools, online consultation services, a clinical communication and collaboration mobile platform and a clinical research integration solution.
LATEST FUNDING	VALUATION	
\$32.0M (Series C)	\$188.2M	
INC. DATE	MATURITY SCORE	
4/2011	81.5	

Spotlight: Ventures with 10 or More Pharmaceutical Partnerships



Elligo Health Research

COUNTRY	PRIMARY CATEGORY	DESCRIPTION
United States	Clinical Trials	Elligo Health Research provides a platform that improves access to clinical trials by surfacing eligible patients and offering providers the personnel, processes, technology and infrastructure necessary to conduct studies in their own clinics
LATEST FUNDING \$135.0M (Series E)	VALUATION \$1.04B	
INC. DATE 3/2016	MATURITY SCORE 78.2	



Phesi

COUNTRY	PRIMARY CATEGORY	DESCRIPTION
United States	Clinical Trials	Phesi has the industry's most comprehensive and dynamic clinical trials database and predictive analytics tools to help trial sponsors make quick and informed decisions to expedite drug development. Their distinguished team works side-by-side with its clients to analyze data, answer questions, and offer informed solutions to benefit study sponsors, investigators, and ultimately patients. Their experts work with study sponsors to drive solutions from clinical development planning through trial implementation to optimize protocol designs, select the best investigator sites, shorten enrollment cycle times, select and manage CROs, and much more.
LATEST FUNDING \$10.0M (Series A)	VALUATION \$45.0M	
INC. DATE 5/2007	MATURITY SCORE 67.5	

**KEY
INFORMATION**





KEY INFORMATION

SCOPE OF REPORT

This report covers HealthTech ventures with incorporation date after 2002. The data is valid as at 1st November 2021.

HealthTech is defined as the intersection between healthcare and technology, and is also referred to as Digital Health. HealthTech does not include Biotech (protein research or pharmaceuticals), MedDev (devices that are mechanical and electronic in nature), neuro-stimulates, opioids and minimally-invasive instruments. We recommend reviewing our taxonomy on the next page for further details.

DATA SOURCING AND TRACKING

Galen Growth tracks a comprehensive inventory of key data points ranging from company demographics, funding and valuation to in-market capabilities on a continuously growing and curated list of HealthTech ventures drawn from global markets. Data is collated from primary research, public domain sources (press releases, news, public fillings), proprietary analytics and from its unique network.

The information is:

- Disclosed and undisclosed by nature
- Continuously updated with the latest data
- Curated from both direct and indirect verified sources
- Augmented with our proprietary algorithms

Each HealthTech Alpha Index and Score is calculated using proprietary algorithms and data points drawn from our carefully curated HealthTech Alpha database. We recommend reviewing our venture spotlights for further insights.

KEY TERMS AND DEFINITIONS

BASE CURRENCY	USD
EARLY STAGE	All deals up to and including Pre-A & Series A stage
GROWTH STAGE	All deals at Series B & C stage
LATE STAGE	All deals at Series D & Beyond stage
EXIT	IPO and M&A deals
HTA	HealthTech Alpha

IMPORTANT INFORMATION

This report is provided solely for informational purposes and was prepared in good faith on the basis of public information available at the time of publication without independent verification. Numbers will be updated from to time to reflect information identified after the event.

Galen Growth does not guarantee or warrant the reliability or completeness of the data nor its usefulness in achieving any particular purposes.

Galen Growth shall not be liable for any loss, damage, cost or expense incurred by reason because of any persons use or reliance on this report.

This report is a proprietary aggregation of publicly available and undisclosed data and shall not be forwarded or reproduced without the prior written consent of Galen Growth.

RESEARCH INQUIRIES

For more information about data, research and Galen Growth's proprietary algorithm contact: dario.heyman@galengrowth.com for more information.

Our Digital Health Taxonomy

Health Management Solutions

- EHR / EMR
- Hospital
- Pharmacy
- Physician / Clinic
- Prescriptive Analytics

Health Services Search

- Medical Concierge
- Medical Tourism
- Track & Trace
- Triage

InsurTech

- Health Claim Management
- Health Insurance
- Medical Payments

Medical Diagnostics

- Diagnosis Tools
- Genomics Related Diagnosis
- Liquid Biopsy
- Medical Imaging

Medical Education

- Consumer Education
- HCP Education
- Health Information Platform

Online Health Communities

- Patient Health Forums
- Physician Networks
- Other HCP Networks

Online Marketplace

- Consumer Marketplace
- On-demand Lab Tests
- Professional Marketplace

Patient Solutions

- Digital Therapeutics
- Disease Management
- Patient Self-Diagnosis

Population Health Management

- Corporate Health
- Integrated Solutions

Remote Monitoring

- Care Coordination
- Home Healthcare
- Remote Monitoring Devices

Research

- Clinical Trials
- Drug Discovery
- Genomics Related Research
- Next Generation Sequencing

Telemedicine

- Teleconsultation
- Telepathology
- Teleradiology
- Telesurgery

Veterinarian

- Animal Imaging
- Animal Monitoring
- Health Forums

Wellness

- Wellness Apps
- Smart Equipment
- Wearables
- Genomics Related Applications
- Wellness Information Platform

Safety & Security

- Counterfeit Tracking
- Cybersecurity

Healthcare Logistics

- Transportation Management
- On-demand Delivery

Others

- Contamination Management
- HCP Job Board
- Social Enterprise
- Software Provider


Analytics Relevant to Decision-Making

Galen Growth's **Alpha Score** is a **360° Venture Maturity assessment** that aggregates a set of composite indices, which are calculated for each venture based on our proprietary algorithms that leverage and analyse over 100 million data points.

There are four distinct and independent Alpha Indices:

- Momentum Index:** Evaluates the maturity and performance of the HealthTech venture relative to itself and ecosystem peers
- Market Index:** Measures the health of the sector category and sub-category in which a startup competes
- Money Index:** Quantifies the financial strength and wellbeing of a HealthTech startup based on its financial history, and investor quality
- Innovation Index:** Assesses the relevance of an HealthTech venture to the ecosystem

The **Alpha Score (also known as Maturity Score)** can be calculated for a venture relative to the Global venture ecosystem or to its National or Regional ecosystem.



**ABOUT
GALEN GROWTH**





Unleash HealthTech Innovation.

NORTH AMERICA | ASIA PACIFIC | EUROPE | MIDDLE EAST

We enable our clients across the world to achieve their ambitions in Digital Health.


From strategic advisory work, enabling companies to understand complex market problems, scouting for specific HealthTech solutions to solve problem statements, through to corporate venturing.

With our specialist knowledge, Digital Health data and deep connections in the HealthTech ecosystem, we help companies change healthcare for the better.



Our Differentiators

Our unique combination of data, analytics, specialist team and Digital Health network, enables our clients to outperform their competition



Global HealthTech Ecosystem Coverage.

Our unmatched coverage of the world's most innovative HealthTech ventures means more innovation choice and better outcomes. Our Asia and European offices serve clients worldwide.

Specialist Team with Decades of Experience

With decades of experience, our team of analysts, researchers, insurance & pharmaceutical industry experts, extend your team with specialist insights and skills.



Tailored Innovation Solutions.

Whatever stage you are in your innovation journey, we have a world class solution to enable you to succeed. Every solution leverages our unrivalled HealthTech data.



HealthTech Alpha

Real-time data, analysis and news at your fingertips

HealthTech Alpha empowers investors, corporates and startups to fast track their Digital Health strategy by transforming tens of millions of ecosystem data points into valuable insights, to rapidly and confidently select best fit ventures for growth.

8100+

STARTUPS

8700+

INVESTORS

22000+

PARTNERSHIPS

7500+

CORPORATES



Rapidly
Shape Your
Decisions



Unlock
Vital
Insights




Accelerate
Your
Strategy

Our Partners

International Pharmaceutical & Insurance companies, VC firms & Investors, rely on Galen Growth to deliver against their Digital Health objectives

Let's Discuss How Galen Growth Can Deliver Your Strategic Healthcare Goals.



Contact Us Now.

✉ **For Pharmaceutical & Medical Devices**
julien.desalaberry@galengrowth.com

✉ **For Insurance**
matt.whittingham@galengrowth.com

✉ **For Europe**
julien.desalaberry@galengrowth.com

✉ **For Japan**
hajime.sato@galengrowth.com

✉ **For Pharmaceutical & Med Dev APAC**
ana.kollcaku@galengrowth.com